Could an Alzheimer's drug slow Parkinson's? new study aims to find out.
NCT ID NCT07544953
First seen Apr 25, 2026 · Last updated May 22, 2026 · Updated 4 times
Summary
This study tests whether lecanemab, a drug that clears amyloid plaques in Alzheimer's disease, can also help people with Parkinson's disease who have amyloid buildup in their brains. About 60 adults aged 50-90 with mild cognitive impairment or early dementia will receive lecanemab for 18 months. Researchers will measure changes in amyloid levels and thinking skills to see if the drug can slow Parkinson's progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yonsei University College of Medicine
Seoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.